Successful Treatment with Everolimus of Functioning Liver Metastases From a Pancreatic Insulinoma Abstract #425

Introduction: Medical treatment of metastatic insulinoma is debated.
Aim(s): To test the efficacy of Everolimus on insulin secretion by liver metastases of a pancreatic insulinoma.
Materials and methods: The patient (66 yrs old) was admitted due to hypoglycemic crises. Glucose=35 mg/dl, insulin =94.9 mUI/l, HbA1c= 4.5% and C peptide =11.1 ng/ml suggested an insulinoma. Abdominal CT showed a 1.5 cm nodule of the head of the pancreas and six metastatic liver nodules. Liver biopsy showed metastases of well-differentiated neuroendocrine carcinoma, G2. The patient underwent a total pancreasectomy with removal of a portion of the gastric wall, spleen, duodenum, gallbladder, right liver lobe. Histology showed a pancreatic well-differentiated neuroendocrine carcinoma, Ki-67= 4%, infiltrating the peri-pancreatic adipose tissue, with metastases to the gastric lymphodes and to the liver. One month after angio-US showed the presence of at least six liver mestastases in the residual left liver, not suitable for radiofrequency ablation. Hypoglycemia recurred, indicating the persistence of insulin production by the metastatic liver in keeping with measurable insulin and C-peptide plasma levels. The patient then started compassionate treatment with Everolimus (10 mg/day).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Maria Chiara Zatelli

To read results and conclusion, please login ...

Further abstracts you may be interested in

#479 Efficacy and Safety of Everolimus in Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Everolimus is a treatment option for patients with pancreatic NETs, while its use in patients with gastrointestinal NETs still remains to be defined.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Maria Rosaria Ambrosio
#2761 Diagnosis and Management of Insulinomas. The Use of Current Practices in Pakistan
Introduction: Insulinomas are rare functional and benign neuroendocrine tumors of Pancreas.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#2737 Identification of a Novel MAFA Missense Mutation Causing Familial Insulinomatosis
Introduction: Insulinomatosis is a rare pancreatic disease characterized by an adult-onset condition of recurrent hyperinsulinemic hypoglycemia caused by multiple insulin-secreting neuroendocrine tumors.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PD. Dr. Christian Fottner
#2983 Differential TGF-β Signalling in Typical and Atypical Bronchial Carcinoids
Introduction: Typical and atypical bronchial carcinoids (TBC and ABC) are well-differentiated neuroendocrine neoplasms (NEN). Metastatic BC having low to moderate mitotic count may still be treated with somatostatin analogues and mTOR inhibitors; however, TBC and ABC have been reported to respond very differently to therapy and an effective treatment algorithm is still lacking. TGF-β is known for its ability to activate mTOR pathway and induce epithelial mesenchymal transition, affecting cell pathophysiological capabilities such as proliferation, migration and tissue invasiveness.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Patricia Borges de Souza
#266 Everolimus Reduces Cell Viability in Selected Human Medullary Thyroid Carcinoma Primary Cultures
Introduction: It has been demonstrated that everolimus, an mTOR inhibitor, has a potent anti-proliferative effect in a human Medullary Thyroid Carcinoma (MTC) cell line, TT, and in two human MTC primary cultures.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Maria Chiara Zatelli